Therapeutic area intelligence for Supportive Care with 30 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 30
Catalysts: 0
Companies: 11

Companies

Accord Biopharma →

ANI Pharmaceuticals →

Barr →

Epic Pharma →

Hikma →

Hope Pharmaceuticals →

Ingenus Pharmaceuticals →

oncology pharma companies →

Pfizer →

Sandoz →

Spectrum Pharmaceuticals →

Assets

Recent signals(30)

RegulatoryAugust 5, 2026

FDA Accepts Supplement Application for Sodium Thiosulfate by Hope Pharms

The FDA has accepted a supplemental application for Sodium Thiosulfate (NDA203923) submitted by Hope Pharms.

RegulatoryAugust 3, 2026

FDA Submission Update for Leucovorin Calcium by Epic Pharma

Epic Pharma's ANDA074544 for Leucovorin Calcium has received an Abbreviated Approval (AP) status.

RegulatoryAugust 3, 2026

FDA Approves Leucovorin Calcium Supplement Application by Ingenus Pharmaceuticals

The FDA has approved the supplemental application ANDA211132 for Leucovorin Calcium submitted by Ingenus Pharmaceuticals.

RegulatoryAugust 3, 2026

FDA Approval Process Update for Leucovorin Calcium by Hikma

The FDA has an active application (ANDA072733) for Leucovorin Calcium submitted by Hikma, currently under standard review.

StrategyAugust 3, 2026

FDA Grants Approval for Leucovorin Calcium ANDA072734 by Hikma

The FDA has granted approval for Hikma's ANDA072734 for Leucovorin Calcium.

RegulatoryAugust 3, 2026

FDA Approval Process Update for Leucovorin Calcium by Hikma

The FDA has an active application for Leucovorin Calcium (ANDA072735) submitted by Hikma, currently under standard review.

RegulatoryAugust 3, 2026

FDA grants approval status for Leucovorin Calcium ANDA072736

The FDA has granted an approval status (AP) for the ANDA072736 application for Leucovorin Calcium submitted by Hikma.

RegulatoryAugust 3, 2026

ANI Pharmaceuticals receives AP status for Leucovorin Calcium supplement

ANI Pharmaceuticals has received an Abbreviated New Drug Application (ANDA) approval status for Leucovorin Calcium.

RegulatoryAugust 3, 2026

FDA Approves Leucovorin Calcium Supplement Application by Barr

The FDA has approved the supplemental application for Leucovorin Calcium submitted by Barr.

RegulatoryAugust 3, 2026

FDA Approval Process Update for Leucovorin Calcium by Barr

The FDA has an active application (ANDA071199) for Leucovorin Calcium submitted by Barr, currently under standard review.

RegulatoryAugust 3, 2026

FDA Approval Status for Leucovorin Calcium Supplement

The FDA has granted an approval status of 'AP' for ANDA213929, a supplement for Leucovorin Calcium.

ClinicalJuly 22, 2026

Spectrum Pharmaceuticals Evaluates Eflapegrastim in Pediatric Cancer Patients

A clinical trial is underway to assess the safety and pharmacokinetics of eflapegrastim in pediatric patients undergoing chemotherapy.

RegulatoryJuly 19, 2026

FDA Approves Supplement for NYVEPRIA (PEGFILGRASTIM-APGF)

The FDA has approved a supplemental application for NYVEPRIA, a pegfilgrastim product.

RegulatoryJuly 15, 2026

FDA Accepts Supplemental Application for ZIEXTENZO by Sandoz

The FDA has accepted a supplemental application for ZIEXTENZO (PEGFILGRASTIM-BMEZ) from Sandoz.

RegulatoryJuly 13, 2026

FDA Accepts Supplement Application for Sodium Thiosulfate by Hope Pharmaceuticals

The FDA has accepted a supplemental application for Sodium Thiosulfate from Hope Pharmaceuticals.

RegulatoryJuly 13, 2026

FDA Accepts BLA for ENNUMO (PEGFILGRASTIM-PCCG) by Accord Biopharma

The FDA has accepted the Biologics License Application for ENNUMO, a pegylated form of filgrastim.

RegulatoryJuly 12, 2026

FDA Accepts ANDA for Leucovorin Calcium by Ingenus Pharmaceuticals

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Leucovorin Calcium submitted by Ingenus Pharmaceuticals.

RegulatoryJuly 12, 2026

Hikma's Leucovorin Calcium ANDA072736 Receives AP Status from FDA

Hikma's ANDA for Leucovorin Calcium has received an Abbreviated Approval (AP) status from the FDA.

StrategyJuly 12, 2026

FDA Grants Approval for Leucovorin Calcium ANDA072734 by Hikma

The FDA has granted approval for Hikma's abbreviated new drug application for Leucovorin Calcium.

RegulatoryJuly 12, 2026

FDA Grants Approval for Leucovorin Calcium Supplement Application

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Leucovorin Calcium submitted by Barr.

StrategyJuly 12, 2026

FDA Grants Approval for Leucovorin Calcium ANDA071199 by Barr

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Leucovorin Calcium submitted by Barr.

RegulatoryJuly 12, 2026

FDA Grants AP Status for Leucovorin Calcium ANDA213929

The FDA has granted approval status (AP) for the ANDA213929 application for Leucovorin Calcium.

RegulatoryJuly 12, 2026

FDA Grants AP Status to Epic Pharma's Leucovorin Calcium Supplement

The FDA has granted approval status (AP) for Epic Pharma's ANDA074544 for Leucovorin Calcium.

ClinicalJuly 9, 2026

Trial of Traditional Chinese Medicine Patch for Cancer-Related Fatigue in Radiotherapy Patients

A randomized controlled trial is evaluating the efficacy of a traditional Chinese medicine patch on cancer-related fatigue during radiotherapy.

ClinicalJuly 5, 2026

Study on Glutamine and Thalidomide for Radiation-Induced Oral Mucositis

A clinical trial is underway to assess the efficacy of glutamine combined with thalidomide in preventing radiation-induced oral mucositis.

ClinicalJuly 3, 2026

Feasibility Study of RestoreMe App for Cancer Patient Nutrition and Activity

Montefiore Medical Center is conducting a feasibility study to assess the RestoreMe app for cancer patients, recruiting 150 participants.

StrategyJuly 2, 2026

Washington University launches multi-site trial on CARE Tool for cancer cost navigation

A multi-site randomized trial is underway to evaluate the CARE Tool, which assists cancer patients in navigating costs and insurance.

ClinicalJune 28, 2026

Study on Digital Psychosocial Screening for Cancer Survivors Launched

A new study is assessing the feasibility of a digital psychosocial screening for cancer survivors to improve care access.

ClinicalJune 17, 2026

Study on Socio-aesthetics Care Impact on Cancer Patients' Quality of Life

A randomized controlled trial is evaluating the impact of socio-aesthetics well-being care on quality of life, pain, and anxiety in cancer patients.

RegulatoryJune 7, 2026

FDA Grants AP Status for MESNA ANDA203364 Submission by RISING

The FDA has granted an Abbreviated Approval (AP) status for the MESNA ANDA203364 submission from RISING.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.